Hims & Hers says it will offer GLP-1 weight-loss drugs, shares surge
Add Axios as your preferred source to
see more of our stories on Google.
The financial promise of weight-loss drugs is giving another company a boost: This time it's Hims & Hers.
Zoom in: The telehealth company's stock soared over 27% Monday after it said it would begin selling compounded versions of the GLP-1 injections that are soaring in popularity.
- The treatments will be offered for $199 monthly, which "includes unlimited medical consultations with a licensed provider" and must be prescribed based on what is "medically appropriate and necessary for each patient," the company said.
Flashback: Hims & Hers CEO Andrew Dudum told Axios in 2023 that the company viewed weight-loss drugs as an "exciting space" and that "it's not a question of will Hims & Hers have a weight offering — it's really just a question of when and how."
The intrigue: Hims & Hers can offer the so-called compounded version of the drugs due to their appearance on the FDA's drug shortages list, Bloomberg noted.
- Drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound have been in short supply, with both companies scrambling to ramp up production.
What to watch: When supplies stabilize, "Hims & Hers plans to make branded options available to customers," the company said.
